IHS Markit
Industry leaders join forces to provide combined news distribution and advanced investor and public relations solutions to enhance stakeholder engagement and increase workflow efficiencies for global companies
LONDON, EN and RALEIGH, NC / ACCESSWIRE / November 18, 2021 / IHS Markit (NYSE:INFO), a world leader in critical information, analytics and solutions, and Issuer Direct Corporation (NYSE American:ISDR), an industry-leading communications company, announced that they will collaborate through a strategic alliance to offer a premier suite of Webhosting, Webcasting and News Distribution products.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Under the agreement, IHS Markit and Issuer Direct, whom together serve the world's leading companies, will give IHS Markit the ability to provide customers with access to a comprehensive communications platform of news distribution, web hosting, design, and webcasting to complement an already best-in-class integrated suite of advanced technology, data science and expertise that helps investor relations professionals target shareholders, communicate effectively, evaluate strategy and improve efficiency.
"This collaboration is a natural next step in support of our Investor Relations clients," said Kelly McGeehan, Head of Issuer Solutions at IHS Markit. "We recently announced the launch of IHS Markit's Capital Access, a platform which empowers IR teams to target and engage investors and prospects while measuring and optimizing success. Today's announced partnership with Issuer Direct will enable our clients to communicate results to the market more efficiently. By combining the power of Capital Access with the efficiency generated through this collaboration, we will now be able to support IR teams more fully throughout their IR workflow. We have a robust partnership network, which enables us to provide outstanding service to companies across all market caps, industries, and geographies, and we are pleased to announce this collaboration with Issuer Direct, a best-in-class provider, which further enhances our ability to deliver for clients."
"We are excited to partner with the IHS Markit team to deliver customers our combined suite of premium services. With over 15 years serving Investor Relations and Public Relations professionals, we will be a significant value add to the current top tier IHS Markit offerings". said Jennifer Hammers EVP of Sales and Marketing for Issuer Direct. "The strategic alliance and partnership will give the IHS Markit IRO customer the ability to take advantage of the most comprehensive technology and distribution in a fast-paced communications landscape."
About Issuer Direct:
Issuer Direct is an industry-leading communications company focusing on the needs of Public Relations and Investor Relations Professionals for over 15 years.Offering a comprehensive suite of communications products, Issuer Direct connects thousands of private and public organizations with journalists, investors, and shareholders, ensuring their most important moments are reaching their audiences. Issuer Direct provides the only flat fee news distribution service through its ACCESSWIRE platform, and is a trusted source for online news for investment professionals for over 4000 companies in over 18 countries. For more information, please visit www.issuerdirect.com.
About IHS Markit
IHS Markit (NYSE:INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 business and government customers, including 80 percent of the Fortune Global 500 and the world's leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.
Issuer Direct Corporation Media Contacts:
Brian R. Balbirnie
+1 919-481-4000
brian.balbirnie@issuerdirect.com
James Carbonara
1+ (646)-755-7412
james@haydenir.com
IHS Markit:
Kate Smith
Tel: +1 781 301 9311
katherine.smith@ihsmarkit.com
SOURCE: IHS Markit and Issuer Direct Corp.
View source version on accesswire.com:
https://www.accesswire.com/673145/IHS-Markit-and-Issuer-Direct-Announce-Strategic-Alliance-and-Partnership
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
